ClinicalTrials.gg
CompletedNCT07042945Updated Jun 22, 2026

MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003)

A Phase 1 interventional study of MK-4646 in HIV Infection, sponsored by Merck Sharp & Dohme LLC. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 75 studies in HIV Infections by Merck & Co., Inc — 1 open to participants now, 2 under way, 1 of them phase 3. HIV Infections · Merck & Co., Inc.

Enrollment
57th of 66
15 · median 163
Started
2025
the only one that year
Phase 1
11 of 75
none open now
Registered
74th of 75
by date

Among the 75 studies in HIV Infections by Merck & Co., Inc, this one is the 57th largest by enrollment of the 66 interventional ones that give a count, is the only one that started in 2025, is one of 11 in phase 1, and was the 74th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

Browse HIV Infections studies →

Open to participants now

1 of the 75 studies in HIV Infections by Merck & Co., Inc is open now. Recruiting first, the newest first:

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in HIV Infections by Merck & Co., Inc, or all of them as a file.
02

Study summary

This study will examine if at least one dose level of MK-4646 can lower HIV-1 viral load in a person's blood by a certain amount. The goals of this study are to learn about the safety of MK-4646 and if people tolerate it; and how HIV-1 viral load may decrease after starting to take MK-4646.

03

Conditions studied

  • HIV Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Other than having -1, is in good health
  • Is antiretroviral therapy (ART)-naïve
  • If ART-experienced has not received any antiretroviral therapy within 60 days (or 5 half-lives, whichever is longer) prior to screening
  • Is willing to receive no other ART prior to Day 8 post-dose of the trial
  • If capable of producing sperm agrees to use
  • If assigned female sex at birth is not breastfeeding
  • A participant of (POCBP) is not pregnant and has a negative highly sensitive pregnancy test (urine or serum), and uses a contraceptive method that is highly effective

Exclusion criteria

Exclusion Criteria:

  • Has acute (primary) -1 infection
  • Has history of endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
  • Is mentally or legally incapacitated, has significant emotional problems at the time of prestudy (screening) visit or expected during the conduct of the study or has a history of clinically significant psychiatric disorder of the last 5 years.
  • Has history of cancer ()
  • Has history of significant multiple and/or severe allergies
  • Tests positive for surface antigen (HBsAg), antibodies
  • Has had a major surgery and/or donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit
  • Has received any vaccine starting from 30 days prior to study intervention or is scheduled to receive any vaccine through 14 days following study intervention
  • Is unable to refrain from using protocol specified prohibited medications
  • Is an excessive smoker, or consumes excessive amounts of alcoholic or caffeinated beverages
  • Is a regular user of any illicit drugs or has a history of drug (including alcohol) abuse
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    MK-4646 Panel A

    MK-4646 160 mg every 24 hours (q24h) for 7 days

    Drug: MK-4646

  • Experimental
    MK-4646 Panel B

    MK-4646 ≤460 mg q24h for 7 days

    Drug: MK-4646

  • Experimental
    MK-4646 Panel C

    MK-4646 ≤460 mg q24h for 7 days

    Drug: MK-4646

  • Experimental
    MK-4646 Panel D

    MK-4646 ≤460 mg every 12 hours (q12h) for 7 days

    Drug: MK-4646

Interventions

  • MK-4646 in capsular form administered orally

06

What researchers measure

Primary outcomes

  1. Participants with averse events (AEs)

    Percentage of participants with one or more AEs

    Time frame: 14 days post last dose (Up to Day 23)

  2. Participants who discontinued study medication due to an AE

    Percentage of participants who discontinued study medication due to an AE

    Time frame: Up to Day 7

  3. Viral load decline of plasma HIV-1 ribonucleic acid (RNA)

    Time course of plasma HIV-1 RNA viral load decline.

    Time frame: Predose, 1,2, 3, 4 and 5 days postdose

Secondary outcomes

  1. Area under the curve from time 0 to 24 hours (AUC0-24) of MK-4646

    AUC0-24 postdose of plasma MK- 4646 in the fasted state

    Time frame: Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24 hours postdose

  2. Maximum plasma concentration (Cmax) of MK-4646

    Cmax postdose of plasma MK- 4646 in the fasted state

    Time frame: Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24 hours postdose

  3. Concentration at 24 hours (C24) of MK-4646

    C24 postdose of plasma MK- 4646 in the fasted state

    Time frame: 24 hours postdose

  4. Time to maximum concentration (Tmax) of MK-4646

    Tmax postdose of plasma MK- 4646 in the fasted state

    Time frame: Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24 hours postdose

  5. Half life (t1/2) of MK-4646

    T1/2 postdose of plasma MK- 4646 in the fasted state

    Time frame: Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24 hours postdose

07

Study locations

2 sites
  • PMSI Republican Clinical Hospital "T.Mosneaga" ( Site 0002)
    Chisinau, 2025, Moldova
  • ARENSIA Exploratory Medicine ( Site 0001)
    Bucharest, Bucharest 021105, Romania
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Jun 2026, 10 months.

Of 74 industry-sponsored phase 1 interventional studies under HIV Infections, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 10 months is above that.

Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2025
First posted
Jun 29, 2025
StartActual
Jul 9, 2025
Primary completionActual
Jun 5, 2026
CompletionActual
Jun 5, 2026
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07042945
Responsible party
Sponsor
First posted
Jun 29, 2025
Start date
Jul 9, 2025
Primary completion
Jun 5, 2026
Completion
Jun 5, 2026
Last update
Jun 22, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MK4646

Start the discussion